CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Naproxen Oral Suspension

Naproxen· ingredient naproxenAntiinflammatory preparations, non-steroids for topical use· NAPROXEN 125 mg/5mL; NAPROXEN 25 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.17537
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per ML — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other naproxen products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.

ProductNADAC / MLvs this
Naproxen$0.05893−$0.11640
Naprotin$0.06254−$0.11280
24/7 Life by 7-Eleven Naproxen Sodium$0.06496−$0.11040
Aleve$0.14651−$0.02890
Naproxen sodium$0.22001+$0.04460
Aleve-D Sinus and Cold$0.24430+$0.06890
Naproxen$1.91+$1.73
Naprelan$9.28+$9.10

Medicare Part D coverage · CY2026

On 70 plan formularies · typical tier 4
Prior auth 9% · Step therapy 0% · Quantity limit 39% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.